Arijit Roy

Dr. Arijit Roy


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2021 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
NBNavneet Bung
Navneet Bung
SKSowmya Ramaswamy Krishnan
Sowmya Ramaswamy Krishnan
GBGopalakrishnan Bulusu
Gopalakrishnan Bulusu
ARArijit Roy
Arijit Roy
Background: The novel coronavirus SARS-CoV-2 has severely affected the health and economy of several countries. Multiple studies are in progress to design novel therapeutics against the potential t...

25 January 2021 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
SKSowmya Ramaswamy Krishnan
Sowmya Ramaswamy Krishnan
NBNavneet Bung
Navneet Bung
GBGopalakrishnan Bulusu
Gopalakrishnan Bulusu
ARArijit Roy
Arijit Roy

14 November 2021 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
SKSowmya Ramaswamy Krishnan
Sowmya Ramaswamy Krishnan
NBNavneet Bung
Navneet Bung
SVSarveswara Rao Vangala
Sarveswara Rao Vangala
RSRajgopal Srinivasan
Rajgopal Srinivasan
GBGopalakrishnan Bulusu
Gopalakrishnan Bulusu
ARArijit Roy
Arijit Roy

22 January 2024 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
SKSowmya Ramaswamy Krishnan
Sowmya Ramaswamy Krishnan
ARArijit Roy
Arijit Roy
Michael GromihaMichael Gromiha
Michael Gromiha
Ribonucleic acids (RNAs) play important roles in cellular regulation. Consequently, dysregulation of both coding and non-coding RNAs has been implicated in several disease conditions in the human body. In this regard, a growing interest has been observed to probe into the potential of RNAs to act as drug targets in disease conditions. To accelerate this search for disease-associated novel RNA targets and their small molecular inhibitors, machine learning models for binding affinity prediction were developed specific to six RNA subtypes namely, aptamers, miRNAs, repeats, ribosomal RNAs, riboswitches and viral RNAs. We found that differences in RNA sequence composition, flexibility and polar nature of RNA-binding ligands are important for predicting the binding affinity. Our method showed an average Pearson correlation (r) of 0.83 and a mean absolute error of 0.66 upon evaluation using the jack-knife test, indicating their reliability despite the low amount of data available for several RNA subtypes. Further, the models were validated with external blind test datasets, which outperform other existing quantitative structure-activity relationship (QSAR) models. We have developed a web server to host the models, RNA-Small molecule binding Affinity Predictor, which is freely available at: https://web.iitm.ac.in/bioinfo2/RSAPred/.

4 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
HBHenry J. Bailey
Henry J. Bailey
GBGustavo A. Bezerra
Gustavo A. Bezerra
JMJason R. Marcero
Jason R. Marcero
SPSiladitya Padhi
Siladitya Padhi
WFWilliam R. Foster
William R. Foster
WYWyatt W. Yue
Wyatt W. Yue
5′-aminolevulinate synthase (ALAS) catalyzes the first step in heme biosynthesis, generating 5′-aminolevulinate from glycine and succinyl-CoA. Inherited frameshift indel mutations of human erythroid-specific isozyme ALAS2, within a C-terminal (Ct) extension of its catalytic core that is only present in higher eukaryotes, lead to gain-of-function X-linked protoporphyria (XLP). Here, we report the human ALAS2 crystal structure, revealing that its Ct-extension folds onto the catalytic core, sits atop the active site, and precludes binding of substrate succinyl-CoA. The Ct-extension is therefore an autoinhibitory element that must re-orient during catalysis, as supported by molecular dynamics simulations. Our data explain how Ct deletions in XLP alleviate autoinhibition and increase enzyme activity. Crystallography-based fragment screening reveals a binding hotspot around the Ct-extension, where fragments interfere with the Ct conformational dynamics and inhibit ALAS2 activity. These fragments represent a starting point to develop ALAS2 inhibitors as substrate reduction therapy for porphyria disorders that accumulate toxic heme intermediates.

27 March 2023 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
DDDibyajyoti Das
Dibyajyoti Das
BCBroto Chakrabarty
Broto Chakrabarty
RSRajgopal Srinivasan
Rajgopal Srinivasan
ARArijit Roy
Arijit Roy